Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 30, 2020. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of insider trading activity.
| Instrument | Transaction Type | Volume | Price (GBP) | Date |
|---|---|---|---|---|
| Ordinary Shares (25p) | Sale (from SIPP) | 8,944 | 13.169 | 2020-10-29 |
| Ordinary Shares (25p) | Purchase | 15,000 | 13.154 | 2020-10-29 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details two separate transactions executed on the same day by Sir Jonathan Symonds, Non-Executive Chairman, on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory compliance document required to disclose PDMR transactions.
Key Facts for Investor Verification
- Insider Activity: Sir Jonathan Symonds, Non-Executive Chairman, executed both a sale and a purchase of GSK shares on October 29, 2020.
- Net Position: The Chairman purchased 15,000 shares and sold 8,944 shares, resulting in a net purchase of 6,056 shares.
- Transaction Source: The sale of 8,944 shares was explicitly noted as being from a Self-Invested Personal Pension (SIPP).
- Market Price: Transactions occurred at approximately £13.15 to £13.17 per share.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or press releases for financial performance data.